DLBCL patients in the low-risk group showed sensitivity to cisplatin (a drug used in several DLBCL second-line chemotherapy regimens) and ABT.263 (Bcl-2 inhibitor, Figure 8B). This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.